Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
0.4068 USD +1.70% Intraday chart for Clene Inc. -8.58% +37.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8 CI
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs CI
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial CI
US FDA finds Clene's trial data for ALS drug to be insufficient RE
Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases CI
Earnings Flash (CLNN) CLENE Reports Q3 Revenue $108M MT
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stocks Look to -2- DJ
Sector Update: Health Care Stocks Advancing Late Afternoon MT
Sector Update: Health Care MT
Clene Shares Jump After Being Awarded $45.1 Million Government Grant for Investigational ALS Drug MT
Clene Awarded $45.1 Million Government Grant to Fund EAP for Investigational ALS Drug MT
Clene Files for Potential Secondary Offering of Up to 3 Million Common Shares MT
Clene Inc. Announces Executive Changes CI
Certain Warrants of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2023. CI
Certain Stock Options of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2023. CI
Certain Common Stock of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2023. CI
Transcript : Clene Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023 11:00 AM
Earnings Flash (CLNN) CLENE Posts Q2 Revenue $269,000 MT
Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures Firmer Despite More China Stress DJ
Benchmark Cuts Price Target on Clene to $5 From $7, Maintains Buy Rating MT
Insider Buy: Clene MT
Chart Clene Inc.
More charts
Clene Inc. is a clinical-stage biopharmaceutical company. The Company is focused on treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. Its drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. Its other products include CNM-ZnAg and CNM-AgZn17. CNM-ZnAg is a spectrum antiviral, antibacterial agent comprised of zinc and silver ions under development to treat infectious disease and to provide immune support for symptom resolution. CNM-AgZn17 is a gel polymer suspension of zinc and silver under development for treatment of infectious diseases and to support wound healing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.4068 USD
Average target price
5 USD
Spread / Average Target
+1,129.11%
Consensus
  1. Stock
  2. Equities
  3. Stock Clene Inc. - Nasdaq
  4. News Clene Inc.
  5. Clene Unit Receives $3 Million Loan From State of Maryland for Manufacturing Facility